Published
January 29, 2026
Updated
July 29, 2026
The $5.5 million Mid America Pet Food settlement covers alleged contamination-related pet injuries and purchases; final approval is under appeal.
Current Status
The court granted final approval on February 6, 2026, but the official administrator reports that two appeals remain pending. Payments cannot be issued until the appeals are resolved, and no distribution date has been announced.StatusFinal approval granted; appeals pending
Claim DeadlineFebruary 5, 2026 (Passed)
Settlement Fund$5.5 million
Payment TimingAfter appeals and claim processing
What Was This Case About?
The lawsuit alleged that certain Mid America Pet Food products were contaminated with Salmonella and posed risks to pets and people. Mid America denied the allegations and liability, and the settlement avoids further litigation.Who Was Covered?
The class generally includes people and entities in the United States who bought covered products from October 31, 2022 through February 29, 2024, subject to the exclusions in the settlement notice.What Benefits Were Available?
The plan provided reimbursement for documented covered-product purchases and qualifying pet injuries, including documented pet-injury losses up to $100,000 per valid claim. Lower capped benefits were available for certain claims supported only by a declaration, subject to the plan and any pro rata adjustment.Official Information
Review current notices and court documents on the Mid America Pet Food Settlement website.
Settlement Fund
$5.5 million
Case Title
Filardi v. Mid-America Pet Food, LLC
Case Number
7:23-cv-11170-NSR
Court
U.S. District Court for the Southern District of New York
Current Milestone
Final approval granted; two appeals pending
Official Website
Mid America Pet Food Settlement
For more class actions, recalls, and refunds, keep scrolling below.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
